Project
A multicenter, prospective observational RWE study to assess Patient-reported wellbeing using tildrakizumab in a live setting – POSITIVE Study
Ongoing - recruitment active · 2022 until 2024
Saulite Ieva
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2022
End Date
2024
Financing
Industry